金融界7月3日消息，上证指数高开震荡，中证ECPI ESG可持续发展40指数 (ESG 40，000970)上涨 0.2%，报1654.07点，成交额282.54亿元。 数据统计显示，中证ECPI ESG可持续发展40指数近一个月上涨1.04%，近三个月上涨0.87%，年至今下 跌2.56%。 从中证ECPI ESG可持续发展40指数持仓的市场板块来看，上海证券交易所占比100.00%。 从中证ECPI ESG可持续发展40指数持仓样本的行业来看，工业占比34.29%、金融占比12.54%、公用事 业占比11.95%、原材料占比9.53%、主要消费占比6.85%、可选消费占比6.84%、医药卫生占比5.36%、 能源占比4.46%、信息技术占比3.22%、通信服务占比2.63%、房地产占比2.32%。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年1月和7月的第二个星期五的下一交 易日。每次调整的样本比例一般不超过10%，除非从样本空间中被调出的老样本数量超过10%。对于调 整前后评级相同的老样本，如果日均总市值在样本空间的排名在前60%，将优先保留。权重因子随样本 定期调整而调整，调整时间与指 ...

金融界6月20日消息，上证指数低开震荡，中证ECPI ESG可持续发展40指数 (ESG 40，000970)上涨 0.22%，报1623.73点，成交额272.32亿元。 数据统计显示，中证ECPI ESG可持续发展40指数近一个月下跌1.72%，近三个月下跌1.44%，年至今下 跌4.16%。 据了解，中证ECPI ESG可持续发展40指数根据 ECPI ESG 评级方法，从上证180公司治理指数样本中选 取ESG评级较高的40只上市公司证券作为指数样本，以反映上证180公司治理指数中ECPI ESG评级较高 上市公司证券的整体表现。该指数以2010年06月30日为基日，以1000.0点为基点。 从中证ECPI ESG可持续发展40指数持仓的市场板块来看，上海证券交易所占比100.00%。 从中证ECPI ESG可持续发展40指数持仓样本的行业来看，工业占比34.49%、公用事业占比12.09%、金 融占比12.07%、原材料占比9.40%、主要消费占比7.11%、可选消费占比6.82%、医药卫生占比5.35%、 能源占比4.50%、信息技术占比3.19%、通信服务占比2.66%、房地产占比2.31%。 ...

本文源自：金融界 金融界6月13日消息，上证指数低开低走，中证ECPI ESG可持续发展40指数 (ESG 40，000970)下跌 0.22%，报1634.71点，成交额445.28亿元。 数据统计显示，中证ECPI ESG可持续发展40指数近一个月上涨0.09%，近三个月上涨0.34%，年至今下 跌3.30%。 据了解，中证ECPI ESG可持续发展40指数根据 ECPI ESG 评级方法，从上证180公司治理指数样本中选 取ESG评级较高的40只上市公司证券作为指数样本，以反映上证180公司治理指数中ECPI ESG评级较高 上市公司证券的整体表现。该指数以2010年06月30日为基日，以1000.0点为基点。 从指数持仓来看，中证ECPI ESG可持续发展40指数十大权重分别为：生益科技（3.1%）、兴业银行 （3.07%）、新华保险（3.01%）、恒瑞医药（3.0%）、三一重工（2.86%）、巨化股份（2.82%）、华 能国际（2.79%）、农业银行（2.77%）、大秦铁路（2.76%）、华电国际（2.76%）。 从中证ECPI ESG可持续发展40指数持仓的市场板块来看，上海证券交易所占比100. ...

SPEC 成功倡导修改美国法律，重新启用包容性基准制定弗吉尼亚州盖恩斯维尔, June 05, 2025 (GLOBE NEWSWIRE) -- 值得信赖的计算基准测试领导者标准性能评估公司（SPEC）今日宣布，SPEC国际标准组织（ISG）成功推动美国明确出口政策，允许美国工业和安全局（BIS）实体名单上的公司参与标准制定。SPEC ISG诚邀因政策原因被排除在合作之外的成员公司回归，汇聚全球产学研力量，共同合作制定未来的计算能效标准。 几年前，为了确保5G技术的安全应用，美国政府规定美国机构不得与BIS实体清单上的企业合作。这项禁令从未针对限制全球标准的制定工作。然而，由于BIS最初的豁免条款中对“标准”一词的定义过于严格，SPEC SERT套件被归类为受限技术，这使得SPEC（一个包含12家中国成员企业的国际标准组织）无法继续与其实体名单上的成员制定标准。 协调的标准最适合一致的设计和监管要求，从而显著降低制造商满足全球额外基准要求的成本 SPEC主席戴维·David Reiner 示：“限制实体名单上的公司参与能效基准的制定，可能会分裂全球标准进程，从而阻碍标准化的首要目标。经过多年的努力，并与其他国 ...

封装技术最早是以双列直插封装DIP为主的直插型封装。到了20世纪80年代，顺应电子设备系统小型化 和集成电路薄型化的要求，封装技术迎来第一次重大变革，从通孔插装进入到表面贴装时代，衍生出了 SOP（Small Out-line Pacakage，小外形封装）、LCC（Leadless Chip Carrier，无引脚芯片载体）以及 QFP（Quad Flat Package，扁平方形封装）等。20世纪90年代前中期，封装技术发生第二次重大变革， 以BGA（Ball Grid Array Package，球栅阵列封装）为代表的先进封装技术开始涌现，封装朝着高引脚 数量、高集成的方向迈进。20世纪90年代中期至2000年后，随着封装尺寸进一步缩小以及工作频率增 加，CSP（Chip-Scale Package，芯片级封装）、WLP（Wafer-Level Package，晶圆级封装）、SIP （System In a Package，系统级封装）、2.5D/3D封装等开始出现，由此半导体封装正式进入先进封装时 代。 传统封装主要是用引线框架承载芯片的封装形式，而先进封装引脚以面阵列引出，承载芯片大都采用高 性能多 ...

Acadia Pharmaceuticals Conference Call Summary Company Overview - **Company**: Acadia Pharmaceuticals (ACAD) - **Event**: BofA Healthcare Conference - **Date**: May 13, 2025 Key Industry Insights - **Most Favored Nation (MFN) Executive Order**: - No immediate impact on Acadia as it currently does not sell products outside the US [3] - Plans to commercialize Debut in Europe, with regulatory approval expected in Q1 2026 [4] - Initial launch in Germany with free pricing for the first six months [4] - **Tariffs**: - Acadia does not foresee meaningful exposure to tariffs due to existing inventory in the US that can last until the mid to late 2030s [7][9] - No manufacturing facilities owned, allowing flexibility in response to future tariff changes [8] - **FDA Interactions**: - No immediate negative impacts reported; routine interactions with the FDA are proceeding as expected [17][18] Company-Specific Developments - **Debut Launch**: - Initial strong demand followed by stagnation; new Chief Commercial Officer hired to enhance commercial execution [21][22] - Field force increased by 30% to improve outreach to physicians, particularly in local pediatric neurology centers [23] - Focus on efficacy messaging and one-to-one patient interactions to improve patient retention [24][25] - New patient starts have shown a significant increase in Q1 2025, with expectations for continued growth [26][36] - **NUPLAZID**: - Awareness campaigns have led to the best quarter in five years for new patient starts [49] - Focus on educating patients and families about Parkinson's disease psychosis, with a strong emphasis on early diagnosis [50][52] - Steady growth expected as awareness increases, with a larger patient population compared to Debut [55] Pipeline Updates - **ACP-101**: - Phase 3 trial expected to complete enrollment in Q2 2025, with top-line data anticipated in early Q4 2025 [58][60] - Primary endpoint focuses on the hyperphagia questionnaire, with a safety profile similar to previous trials [61][62] - **ECP-204**: - New inverse agonist targeting 5-HT2A receptors, currently in phase 2/3 trials for Alzheimer's disease psychosis [73] - Aiming for faster onset of action and reduced QT prolongation compared to NUPLAZID [74] Additional Considerations - **Market Dynamics**: - The rare disease market is seen as having room for multiple therapies, with Acadia's products positioned to meet diverse patient needs [66][70] - The company is focused on leveraging its expertise in rare diseases and neurology for successful product launches [71] - **Future Events**: - R&D Day scheduled for June 25, 2025, to provide further updates on pipeline developments [79]

Investment Rating - The investment rating for the company is "Buy" and is maintained [7] Core Views - The company is expected to achieve revenue of 29.84 billion yuan in 2024, representing a year-on-year growth of 35.14%, and a net profit attributable to shareholders of 5.62 billion yuan, up 44.17% year-on-year [2][9] - The company is accelerating its platform layout, with significant breakthroughs in key technologies for new products, leading to a steady increase in market share for mature products [2][3] - The company has announced its entry into the ion implantation equipment market and has launched several new products, enhancing its competitive position in the semiconductor equipment sector [3][4] Financial Performance - The company is projected to achieve revenues of 38.79 billion yuan, 48.71 billion yuan, and 58.74 billion yuan in 2025, 2026, and 2027 respectively, with corresponding net profits of 7.38 billion yuan, 9.72 billion yuan, and 12.15 billion yuan [7][9] - The company's earnings per share (EPS) is expected to grow from 10.52 yuan in 2024 to 22.75 yuan in 2027, reflecting strong profitability [9][12] - The price-to-earnings (P/E) ratio is projected to decrease from 41.50 in 2024 to 19.19 in 2027, indicating an attractive valuation over the forecast period [9][12] Market Position - The company has strengthened its market position by acquiring a 17.90% stake in Chip Source Micro, which will enhance its collaborative capabilities in semiconductor equipment [4][6] - The company has successfully launched high-end equipment in the integrated circuit equipment sector, with revenues from etching, film deposition, thermal treatment, and wet processing equipment expected to exceed 80 billion yuan, 100 billion yuan, 20 billion yuan, and 10 billion yuan respectively in 2024 [2][3]

公司基本情况 | 最新收盘价（元） | 436.68 | | --- | --- | | 总股本/流通股本（亿股）5.34 | / 5.34 | | 总市值/流通市值（亿元）2,333 | / 2,331 | | 52 周内最高/最低价 | 486.69 / 283.86 | | 资产负债率(%) | 51.0% | | 市盈率 | 41.30 | | 第一大股东 | 北京七星华电科技集团 | | 有限责任公司 | | 研究所 分析师:吴文吉 SAC 登记编号:S1340523050004 Email:wuwenji@cnpsec.com 分析师:翟一梦 SAC 登记编号:S1340525040003 Email:zhaiyimeng@cnpsec.com 证券研究报告：电子 | 公司点评报告 股票投资评级 买入 |维持 北方华创(002371) 平台型布局加速推进 l 投资要点 成熟产品市占稳步提升，新产品关键技术持续突破。2024 年 公司持续深化半导体基础产品领域布局，核心业务保持高速增长， 2024 年公司实现营收 298.38 亿元，同比+35.14%；归母净利润 56.21 亿元，同比+44.17 ...

金融界5月12日消息，上证指数高开高走，中证ECPI ESG 80指数 (ESG 80，931148)报1903.98点。 数据统计显示，中证ECPI ESG 80指数近一个月上涨2.74%，近三个月上涨0.15%，年至今下跌2.90%。 据了解，中证ECPI ESG 80指数从沪深300样本中选取ESG评分在E+以上、过去6个月波动率最低的80只 证券作为指数样本，采用波动率倒数加权，为投资者提供更多样化的投资标的。该指数以2011年06月30 日为基日，以1000.0点为基点。 从指数持仓来看，中证ECPI ESG 80指数十大权重分别为：国泰海通（2.82%）、长江电力（2.09%）、 大秦铁路（2.08%）、浦发银行（2.04%）、成都银行（2.04%）、上海银行（1.96%）、农业银行 （1.8%）、民生银行（1.8%）、光大银行（1.73%）、北京银行（1.65%）。 从中证ECPI ESG 80指数持仓的市场板块来看，上海证券交易所占比73.30%、深圳证券交易所占比 26.70%。 从中证ECPI ESG 80指数持仓样本的行业来看，金融占比34.22%、工业占比22.32%、原材料占比 11 ...

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $172 million, an increase of 13% compared to Q1 2024 [13][25] - Shipments were $157 million, down 36% year-over-year, attributed to strong demand in Q1 2024 [13][26] - Gross margin was 48.2%, exceeding the target range of 42% to 48% [14][27] - Net cash increased to $271 million from $259 million at the end of 2024 [14][29] Business Line Data and Key Metrics Changes - Revenue from single wafer cleaning tools grew 18%, representing 75% of total revenue [15] - Revenue from ECP, furnace, and other technologies grew 7%, accounting for 16% of total revenue [16] - Revenue from advanced packaging, excluding ECP, was down 10.5%, representing 9% of total revenue [19] Market Data and Key Metrics Changes - In China, the company estimates its market share in wafer cleaning and plating exceeded 25%, translating to over 9% globally for each category [7] - The company is expanding its business into the global market, with investments in an Oregon facility to reduce tariff uncertainties [11][12] Company Strategy and Development Direction - The company aims to develop world-class tools and establish R&D and production in key countries to support major semiconductor customers [9] - The focus remains on delivering differentiated enabling technology to solve critical process challenges for global customers [24] - The long-term revenue target is set at $3 billion, with equal contributions expected from China and the global market [21] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the shifting global trade environment and its complexities, emphasizing the importance of their established strategy [9] - The company maintains a revenue outlook for 2025 in the range of $850 million to $950 million, implying a 15% year-over-year growth at the midpoint [24] - Management expressed confidence in continued market share growth despite a plateau in the WFE market in China [44][46] Other Important Information - The Oregon facility is being developed to support global customers and is expected to include a clean room and demo lab [23] - The Lingang production and R&D center is nearing completion, with a potential annual production capacity of $3 billion [22] Q&A Session Summary Question: Shipment figures and full-year shipment growth expectations - Management expects shipments to grow in 2025 but acknowledges that the growth rate may not exceed last year's high levels [35][36] Question: Impact of tariffs on profitability - Management believes the impact of tariffs is minimized as they are sourcing more parts locally and from third countries [42] Question: Thoughts on 2026 growth and market conditions - Management indicated that while the WFE market may plateau, they expect to continue gaining market share through innovation and new products [44][46] Question: Domestic competition and potential consolidation in the semiconductor sector - Management expressed confidence in their technology and innovation, stating that local competitors cannot easily replicate their products [52][55]